Breast Cancer Research and Treatment最新文献

{"title":"Dual-modality breast cancer screening compared to MRI or mammography alone among female Hodgkin lymphoma survivors who received chest radiotherapy.","authors":"Eline M J Lammers, Jeanne Beens-van Dijk, Annelies Nijdam, Renée Menezes, Michael Schaapveld, Inge M Krul, Inge-Marie Obdeijn, Flora E van Leeuwen, Cynthia So-Osman, Berthe M P Aleman","doi":"10.1007/s10549-026-07898-5","DOIUrl":"10.1007/s10549-026-07898-5","url":null,"abstract":"<p><strong>Purpose: </strong>Female Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) before the age of 40 years face increased breast cancer (BC) risk. Dutch guidelines recommend annual magnetic resonance imaging (MRI) and mammography at ages 30-60 years starting eight years after RT. Dual-modality screening is burdensome and may increase false positive rates. We therefore compared the diagnostic value of each individual modality with MRI and mammography combined.</p><p><strong>Methods: </strong>Results of dual-modality BC screenings performed in 2005-2021 at two Dutch survivorship clinics were used to estimate sensitivity and specificity for each modality and MRI and mammography combined.</p><p><strong>Results: </strong>We retrospectively reviewed 550 screening rounds in 134 HL survivors (median follow-up: 3 years) during which 19 early-stage tumors occurred. Sensitivity was 79% (95% Confidence Interval (CI): 54-94) for MRI alone, 63% (95% CI: 38-84) for mammography alone and 95% (95% CI: 74-100) for both modalities combined. Specificity was 89% (95% CI: 86-91) for MRI alone, 97% (95% CI: 95-98) for mammography alone and 86% (95% CI: 83-89) when combining modalities. Additional ultrasound was performed in 15.3% of screening rounds (in 74.4% due to MRI findings) and puncture/biopsy in 8.0%.</p><p><strong>Conclusions: </strong>In conclusion, to obtain a sufficiently high screening sensitivity in female HL survivors treated with chest RT, we recommend screening with both MRI and mammography. However, MRI is associated with a high false positive rate. Our findings inform survivors and clinicians about effectiveness of BC screening and its burden.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 3","pages":"64"},"PeriodicalIF":3.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146060094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.","authors":"Katherine Leggat-Barr, Tomiyuri Lewis, Jeffrey A Tice, Elene Tsopurashvili, Rosalyn Sayaman, Paige Warner, Kathy Malvin, Leah Sabacan, Alexandra Perry-Solomon, Sarah Theiner, Irene Acerbi, Ann Griffin, Joseph McGuire, Vivian Lee, Alexander D Borowsky, Martin Eklund, Celia Kaplan, Robert A Hiatt, Allison Stover Fiscalini, Karla Kerlikowske, Yiwey Shieh, Laura Esserman, Laura Van't Veer","doi":"10.1007/s10549-025-07894-1","DOIUrl":"10.1007/s10549-025-07894-1","url":null,"abstract":"<p><strong>Purpose: </strong>Determine the association between the Breast Cancer Surveillance Consortium v2 model (BCSC) risk score and advanced and non-advanced invasive breast cancer (IBC).</p><p><strong>Methods: </strong>We estimated BCSC 5-year invasive breast cancer risk for 11,915 participants in a prospective screening cohort with median follow-up of 6.9 years prior to breast cancer diagnosis. Individuals in the top 25% by age of BCSC risk standard were considered high-risk, those in the bottom 75% low-risk. We obtained cancer outcomes, including American Joint Committee on Cancer (AJCC) prognostic pathologic stage, from the San Francisco Mammography Registry and an institutional cancer registry. We examined the associations of BCSC risk scores with advanced (≥ AJCC prognostic stage II) and non-advanced (AJCC prognostic stage I) IBC using Fisher's exact test and logistic regression.</p><p><strong>Results: </strong>Of 11,915 participants, 4,005 (34%) were high-risk. There were 254 incident IBC cases, of which 40 (16%) were advanced and 214 (84%) were non-advanced. The median 5-year BCSC risk score for women with and without IBC was 1.83% and 1.45%, respectively (p < 0.001). High BCSC risk among women diagnosed with breast cancer was associated with non-advanced cancer (OR = 2.25, 95% CI = 1.71-2.95, p < 0.0001), but not with advanced cancer (OR = 1.20, 95% CI = 0.63-2.29, p = 0.57) compared to women not diagnosed with breast cancer.</p><p><strong>Conclusion: </strong>High BCSC risk scores were associated with high rates of non-advanced IBC. As non-advanced cancers are more likely to be hormone receptor-positive, BCSC may optimally identify candidates for endocrine risk reduction.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 3","pages":"65"},"PeriodicalIF":3.0,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12852213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146060108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second-line treatment strategy following CDK4/6 inhibitors for HR-positive and HER2-negative metastatic breast cancer patients: a multicentric, retrospective, observational study.","authors":"Olivia Lavigne, François Poumeaud, Thibaut Reverdy, Van Tuat Huynh, Guillaume Roces, Gaulthier Poupin, Maureen Gouillou, Angélique Bobrie, Emma Donadille, Florence Dalenc, William Jacot, Julien Robert, Frédéric Fiteni","doi":"10.1007/s10549-025-07893-2","DOIUrl":"10.1007/s10549-025-07893-2","url":null,"abstract":"<p><strong>Purpose: </strong>The standard first-line treatment for patients with hormone receptor-positive (HR +) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer is cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy (ET). Optimal therapy after CDK4/6 inhibitors remains to be determined. We aimed to define the appropriate second-line treatment after CDK4/6 inhibitors in a real-life population.</p><p><strong>Methods: </strong>Patients who had received CDK4/6 inhibitors with aromatase inhibitors (AIs) for HR + /HER2- metastatic breast cancer were included from March 2017 to May 2021 at five French cancer centers.The primary objective was to describe second-line treatment after primary treatment with CDK4/6 inhibitors plus AIs.</p><p><strong>Results: </strong>We included 381 patients who received CDK4/6 inhibitors combined with AIs as first-line therapy. Patients with progressive disease (N = 165) benefited from a second-line of treatment: 69 (41.8%) were treated with chemotherapy, while 90 (54.6%) received endocrine therapy (ET alone: 59, 35.8%; ET plus targeted therapy: 31, 18.8%).Patients on chemotherapy were younger compared to those receiving ET (p = 0.011). Patients experiencing earlier progression were more likely to benefit from chemotherapy than ET (p = 0.001). Patients with visceral disease at diagnosis were more often treated with chemotherapy. Second-line median PFS was 6.4 months (95% CI [5.0-12.9]) for chemotherapy and 8.4 months (95% CI [5.4-11.7]) for ET ± targeted therapy, with no significant difference (HR 1.08, 95% CI [0.73-1.59], p = 0.70).</p><p><strong>Conclusion: </strong>This French real-world study demonstrates limited progression-free survival benefits across all second-line strategies after CDK4/6 inhibitor progression, highlighting an urgent clinical need for more effective post-progression therapies.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 3","pages":"63"},"PeriodicalIF":3.0,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146050418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.","authors":"Claudia Fumarola, Cristina Caffarra, Silvia La Monica, Maricla Galetti, Roberta R Alfieri, Andrea Cavazzoni, Elena Galvani, Daniele Generali, Pier Giorgio Petronini, Mara A Bonelli","doi":"10.1007/s10549-025-07880-7","DOIUrl":"10.1007/s10549-025-07880-7","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"62"},"PeriodicalIF":3.0,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study.","authors":"Qichen Wang, Sarah C Van Alsten, Xiaojia Ji, Esraa Salim, Nicole Salazar, John E Scott, Xiaohe Yang, Rob U Onyenwoke, Melissa A Troester, Kevin P Williams","doi":"10.1007/s10549-025-07884-3","DOIUrl":"10.1007/s10549-025-07884-3","url":null,"abstract":"<p><strong>Purpose: </strong>Inflammatory breast cancer (IBC) has been hypothesized to represent a distinct molecular subtype. However, few IBC-specific gene expression patterns have been identified, and previous genomic studies of IBC have been small with limited information on social determinants.</p><p><strong>Methods: </strong>We identified 153 IBC cases in the Carolina Breast Cancer Study (total N = 4,739). RNA expression was measured on the NanoString platform (N = 74 IBC, 2,696 non-IBC) and used to determine molecular subtypes, including PAM50, immune, homologous recombination deficiency (HRD), and P53 status. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) of associations between IBC and patient demographic, molecular, and social characteristics using logistic regression, and compared differences in gene expression using ANOVA.</p><p><strong>Results: </strong>Women with IBC were associated with Black and under 50 compared to non-IBC. IBC was associated with rural address (OR = 1.53) and poverty (OR = 1.61). Molecularly, IBC was associated with HER2-enriched (OR = 6.14), Luminal B (OR = 2.90), P53 Mutant-like (OR = 1.79), and high HRD (OR = 1.90). Neither adiposity nor immune subtype was significantly associated with IBC. Only six of 219 genes measured were significantly differentially expressed between IBC and non-IBC, including HER2-related (ERBB2, FGFR4, GRB7) and P53-related genes (BTG2, LOC400043, MAP2K4).</p><p><strong>Conclusion: </strong>Although not associated with immune subtypes, IBC showed differences in HER2 and P53 pathways. The association of IBC with rurality and poverty underscores the importance of health care access for timely diagnosis and treatment of IBC.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"61"},"PeriodicalIF":3.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12827424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study.","authors":"Nickolas Stabellini, Jasskiran Kaur, Cynthia Owusu, Bahar Moftakhar, Takae Mizukami, Sonia D de Oliveira, Alberto J Montero","doi":"10.1007/s10549-025-07891-4","DOIUrl":"10.1007/s10549-025-07891-4","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate whether reduced doses (RD) of trastuzumab deruxtecan (T-DXd) or sacituzumab govitecan (SG) provide similar outcomes to the approved standard doses (SD) in metastatic breast cancer (mBC).</p><p><strong>Methods: </strong>This retrospective cohort included mBC patients receiving at least one cycle of SG (April 2021-May 2024) or T-DXd (February 2020-December 2024). Primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan-Meier curves and Log-Rank tests estimated and compared PFS and OS from treatment initiation. Subgroup analyses were performed by HER2 and hormone receptor status.</p><p><strong>Results: </strong>48 patients received SG (24 RD vs. 24 SD) and 66 received T-DXd (29 RD vs. 37 SD). Median PFS for SG was 3 months in both SD (95% CI, 2-10) and RD (95% CI, 2-8; p = 0.8). Median OS for SG was 10 months (95% CI, 7-13) for SD and 11 months (95% CI, 5-30; p = 0.4) for RD. For T-DXd, median PFS was 10.4 months for SD (95% CI, 7.0-14.5) and 11.2 months for RD (95% CI, 5.4-31.1; p = 0.8), while median OS was 18.3 months (95% CI, 13.9-NA) for SD and 28.1 months (95% CI, 18.2-NA; p = 0.9) for RD. Overall response rates were similar between patients receiving RD and SD SG or T-DXd.</p><p><strong>Conclusions: </strong>This real-world data suggest RD of SG or T-DXd achieve outcomes comparable to SD, supporting prospective evaluation of lower-dose regimens.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"59"},"PeriodicalIF":3.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12819492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer.","authors":"José Luis Alonso-Romero, Jerónimo Martínez-García, Raúl Carrillo-Vicente, Antonio Fernández Aramburo, Angélica Ferrando Díez, Pilar Sánchez Henarejos, Pilar de la Morena Barrio, Ana Puertes Boix, Mª Dolores Jiménez, Joaquín Peña Siles, José Antonio Parejo Maestre, Antonio de Las Heras-Rubio, Paula Ruiz Carreño","doi":"10.1007/s10549-026-07895-8","DOIUrl":"10.1007/s10549-026-07895-8","url":null,"abstract":"<p><strong>Background: </strong>Data on neoadjuvant treatment with trastuzumab biosimilars, particularly CT-P6, in combination with pertuzumab, are limited. This study evaluates the efficacy, tolerability, and immunogenicity of CT-P6 plus pertuzumab and chemotherapy, in routine clinical practice for HER2-positive early breast cancer, including translational biomarker analyses related to pathologic complete response (pCR).</p><p><strong>Methods: </strong>Prospective, multicenter, observational study in 102 patients with HER2-positive early breast cancer. Patients received hospital-preferred neoadjuvant regimens protocols, with (scheme 1 and 3) or without anthracyclines (scheme 2). The primary endpoint was pCR, defined as the absence of invasive tumor in both the breast and axillary lymph nodes (ypT0/ypTis and ypN0). Translational endpoints included soluble HER2, anti-trastuzumab CT-P6 antibodies, and exploratory response-related modeling approaches supported by machine learning techniques.</p><p><strong>Results: </strong>Among patients who underwent surgery, pCR (ypT0/ypTis and ypN0) was achieved in 57.43% of cases, with no significant differences between anthracycline-based and non-anthracycline-based regimens. Soluble HER2 and anti-trastuzumab CT-P6 antibodies were not significantly associated with pCR. Treatment was well-tolerated; the most relevant Grade 3-4 treatment-related adverse events were diarrhea (2.25%) and asthenia (0.50%). No immunogenicity or clinically relevant cardiotoxicity was observed.</p><p><strong>Conclusions: </strong>Trastuzumab CT-P6 combined with pertuzumab and chemotherapy can be used in neoadjuvant treatment for HER2-positive early breast cancer, showing pCR rates comparable to the reference trastuzumab and without evidence of immunogenicity. Exploratory analyses of soluble HER2 and anti-trastuzumab CT-P6 antibodies did not demonstrate a significant association with pCR, although this possibility cannot be excluded. Their assessment contributes to the translational understanding of biosimilar integration into curative regimens.</p><p><strong>Trial registration: </strong>The study has been registered in Clinicaltrials.gov ( https://clinicaltrials.gov/study/NCT06907082 ).</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"60"},"PeriodicalIF":3.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12819485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fracture risk in metastatic breast cancer patients treated with CDK 4/6 inhibitors and endocrine therapy.","authors":"Rebecca Pedersini, Laura Moretti, Marta Laganà, Greta Schivardi, Valentin Baluta, Manuel Zamparini, Eleonora Conforti, Marco Ravanelli, Caterina Brentegani, Vito Amoroso, Salvatore Grisanti, Chiara Buizza, Giulia Scartabellati, Michela Bazzoli, Giuseppe Ippolito, Federica Pellicioli, Davide Farina, Alfredo Berruti, Deborah Cosentini","doi":"10.1007/s10549-025-07887-0","DOIUrl":"10.1007/s10549-025-07887-0","url":null,"abstract":"<p><strong>Purpose: </strong>Investigate skeletal morbidity (SM) in metastatic breast cancer (MBC) patients undergoing CDK4/6 inhibitors (CDK4/6is) and endocrine therapy (ET).</p><p><strong>Methods: </strong>In this retrospective study we evaluated skeletal morbidity - defined as the occurrence of skeletal-related events (SREs) in metastatic bone and fragility fractures in non-metastatic bone - in 214 MBC patients who had received ET and CDK4/6is. As secondary aim, we compared VF progression, defined as a new fracture or worsening of a pre-existing fracture at spine CT scan, between 121 patients receiving ET alone (cohort A) and 121 patients on ET plus CDK4/6is (cohort B), balanced using propensity score.</p><p><strong>Results: </strong>Among the 147 patients (68.7%) with bone metastases, 59 (40.1%) experienced SREs including non-vertebral pathologic fractures (17 patients, 11.6%), pathologic VF progression (21 patients, 14.3%), spinal cord compression (3 patients, 2.0%), radiation to bone (18 patients, 12.2%). Considering the non-metastatic bone, 3 out of 214 patients (1.4%) experienced new non-vertebral fragility fractures, and 26 patients (12.2%) had fragility VF progression. In the comparative study, pathologic VF progression in metastatic bone was 38.3% in cohort A and 29.1% in cohort B (p = 0.093). The corresponding fragility VF progression rate in non-metastatic bone was 22.3% and 12.4% (p = 0.031).</p><p><strong>Conclusions: </strong>A considerable proportion of women with MBC treated with CDK4/6is + ET experience SM on both metastatic and non-metastatic bone. Patients treated with CDK4/6is + ET had lower SM than those on ET alone.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"58"},"PeriodicalIF":3.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in postmastectomy radiotherapy for early and locally advanced breast cancer in Switzerland: a population-based cross-sectional and longitudinal analysis.","authors":"Marcel Blum, Sonja Marion Koch, Mohsen Mousavi, Denise Vorburger, Andreas Müller, Michel Eric Nicolas Zimmermann, Christoph Oehler, Daniel Rudolf Zwahlen","doi":"10.1007/s10549-025-07890-5","DOIUrl":"10.1007/s10549-025-07890-5","url":null,"abstract":"<p><strong>Purpose: </strong>Postmastectomy radiotherapy (PMRT) reduces locoregional recurrence and improves survival in high-risk breast cancer (BC), yet its real-world use remains variable. Population-based data on PMRT utilization and guideline adherence in Switzerland are lacking. We evaluated PMRT patterns, determinants, and adherence to ASCO-ASTRO-SSO recommendations among women with stage I-III BC over two time periods and interpreted findings in the context of the 2025 guideline.</p><p><strong>Methods: </strong>This retrospective, population-based study analyzed data from seven Swiss cancer registries, including Eastern Switzerland (2003-2005; n = 4,246), and from Eastern Switzerland alone (2015-2017; n = 976). Eligible patients were women aged ≥ 18 years with stage I-III invasive BC treated by simple mastectomy. PMRT use was examined across original ASCO-ASTRO-SSO-defined risk groups: low-risk (T1-2N0), intermediate-risk (T1-2N1, T3N0), and high-risk (T4 or N2-3). Multivariable regression identified clinicopathologic determinants of PMRT use. Trends in PMRT guideline adherence and regional nodal irradiation (RNI) were evaluated within the framework of evolving clinicobiologic risk paradigms. Overall survival (OS) was analyzed using Kaplan-Meier and Cox regression methods.</p><p><strong>Results: </strong>Overall PMRT utilization remained low (25-30%) across both periods. PMRT was independently associated with younger age, higher T-/N-stage, lymphovascular invasion (p < 0.01), positive margins, G3 histology, and ER negativity (p < 0.05). Adherence to guidelines improved in low-risk patients (93% to 96%) but declined in high-risk patients (64% to 54%), with decreasing PMRT use in T4 (53% to 27%), N2 (73% to 57%), and N3 disease (83% to 73%). In contrast, PMRT use increased among intermediate-risk patients (23% to 39%), particularly in T1-2N1 disease (19% to 38%) and in the presence of adverse features: LVI + (21%), HER2 + (23%), TNBC (30%), G3 (38%), and age < 45 years (57%). Supraclavicular/axillary RNI declined overall but increased in node-negative patients, paralleling reduced axillary dissection and increased sentinel biopsy (26% to 70%). PMRT was not associated with a statistically significant OS benefit; supraclavicular RNI showed a non-significant trend toward improved OS in N2-3 disease.</p><p><strong>Conclusions: </strong>This first national analysis provides real-world evidence that PMRT utilization in Switzerland remains low, with underuse in high-risk patients and selective, biologically informed escalation in intermediate-risk disease. While patterns reflect evolving multidisciplinary care, persistent gaps in ASCO-ASTRO-SSO guideline implementation underscore the need for continued surveillance and individualized, risk-adapted PMRT decision-making.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"57"},"PeriodicalIF":3.0,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145958874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated systematic review and meta-analysis: taking the next step in physical activity behavioral interventions for post-treatment breast cancer survivors.","authors":"Brianna N Leitzelar, Alana R Willis, Sarah N Price, Janet A Tooze, Helena M VonVille, Rachel Lintz, Shirley M Bluethmann","doi":"10.1007/s10549-025-07892-3","DOIUrl":"10.1007/s10549-025-07892-3","url":null,"abstract":"<p><strong>Purpose: </strong>To provide an updated review of the literature on physical activity (PA) intervention studies, their characteristics, and their effect size estimates for PA behavior change among early post-treatment breast cancer survivors (BCS).</p><p><strong>Methods: </strong>Eligible studies were published between 2014-2025 in English, were quasi- or randomized controlled trials, studied BCS ≤ 5 years post-treatment, tested a PA intervention, and assessed PA behavior. We searched PubMed, APA PsycINFO, Embase, and CINAHL (latest search October 2025; CINAHL June 2020). Extracted data included study, participant, intervention, and outcome descriptors. The ROB 2 assessed risk of bias. A random effects model on post-intervention Cohen's d standardized mean differences (SMD) values meta-analysis was performed.</p><p><strong>Results: </strong>Twenty-two RCTs with a total sample size of 2,390 (mean = 109, range = 26-692) were included. All included BCS were female, were on average 57 years old, and predominantly (> 60%) non-Hispanic White. Most study populations were mixed in terms of cancer stage and treatment type. Intervention duration ranged from 6-104 weeks. All studies except one were partially or fully home-based. All behavioral counseling interventions were theory-based. The overall SMD was d = 0.36 (95% confidence interval: 0.22, 0.50) in favor of the intervention. Two studies had some concerns for risk of bias; all others were rated as low.</p><p><strong>Conclusion: </strong>The present updated review found a small-to-moderate positive effect of PA interventions on PA behavior change among early post-treatment BCS. We note some shifts in the participant samples and study design since the originally published review. Practical implications for improving the reporting of future research include following established reporting guidelines to enhance reporting transparency, which would allow for more precise quantification of specific intervention effects and deeper contextual understanding of this body of work.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"215 2","pages":"56"},"PeriodicalIF":3.0,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12790553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}